LDR Announces Presentations of Mobi-C(R) Cervical Disc

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
LDR Announces Presentations of Mobi-C(R) Cervical Disc Five-Year Clinical Results at the North American Spine Society Annual Meeting (NASS)

AUSTIN, Texas, Nov. 13, 2014 (GLOBE NEWSWIRE) -- LDR Holding Corporation (Nasdaq: LDRH ) ("LDR" or the "Company"), a global medical device company focused on designing and commercializing novel and proprietary spinal surgical technologies, announced the Company's significant presence at this year's North American Spine Society (NASS) annual meeting. Five scientific presentations analyzed and discussed the five-year, long-term safety and efficacy data from the Mobi-C Cervical Disc one and two-level prospective clinical trials, including one presentation included in the "best papers" session.

Below is a listing of key research conclusions shared by the authors during each presentation.

Wednesday, November 12, 2014

  • Dr. Reginald Davis of the Greater Baltimore Medical Center and University of Maryland Medical Center presented "Two-Level Treatment With Total Disc Replacement Versus ACDF: Results from a Prospective Randomized Clinical Trial with Five Years Follow-up".
    • Author conclusions:
      • Mobi-C patients maintained segmental range of motion through 60 months compared to anterior cervical discectomy and fusion (ACDF) patients where motion was eliminated.
      • Two-level Mobi-C patients experienced statistically significant benefits over ACDF patients at 60 months in:
        • NDI scores
        • VAS neck pain scores
        • Patient satisfaction
        • Rate of subsequent surgeries.
      • Overall study success rates demonstrate Mobi-C at two contiguous levels to be a superior alternative to ACDF through 60 months.
         
  • Dr. Michael Hisey of the Texas Back Institute presented "One-Level Treatment With Total Disc Replacement and ACDF: Five-Year Results from a Prospective Randomized Clinical Trial".
    • Author conclusions:
      • At 60 months, Mobi-C patients maintained baseline segmental mobility compared to the expected loss of motion in ACDF patients.
      • One-level Mobi-C patients experienced less pain, higher levels of function, and have better quality of life at earlier time points.
      • Long-term evidence reveals one-level Mobi-C to be a safe and effective alternative to ACDF.
      • Mobi-C patients required significantly fewer device related surgical interventions through 60 months.
        • Mobi-C: 3.4% vs. ACDF 12.3%, p < 0.05.
           
  • Dr. Robert Jackson of Orange County Neurosurgical Associates presented "Subsequent Surgery Rates After Treatment With TDR or ACDF at One or Two Levels: Results from an IDE Clinical Trial With Five-Years Follow-Up".
    • Author conclusions:
      • As compared to ACDF, cervical total disc replacement (TDR) with Mobi-C appears to be associated with
        • less adjacent segment degeneration; and
        • less need for additional surgery at index level and adjacent levels in patients with one and two-level cervical disc disease through 60 months.
           
  • Dr. Pierce Nunley of the Spine Institute of Louisiana presented "Radiographic Adjacent Segment Pathology (RASP) After Treatment With TDR or ACDF at One or Two Levels at Five Years".
    • Author conclusions:
      • 1-level cervical TDR patients have less RASP than ACDF at 60 months.
      • At 2 levels the difference between cervical TDR and ACDF is even more pronounced.
      • Greatest changes in RASP (D3 and D4) are observed almost exclusively with ACDF.
      • Cervical TDR should be given due consideration versus ACDF when deciding treatment plan.

Thursday, November 13, 2014

  • Dr. Hyun W. Bae of The Spine Institute in Santa Monica and The Spine Center at Cedars Sinai Medical Center presented "Cervical Total Disc Replacement and Anterior Cervical Discectomy and Fusion: A Comparison of One- and Two-Level Treatment". (NOMINATED BEST PAPER, 2014)
    • Author conclusions:
      • There is no statistically significant reduction in efficacy or increase in complications as the number of levels treated with Mobi-C increases from one level to two levels.
      • ACDF patients demonstrate a reduction in treatment effectiveness when the number of levels operated is increased from one to two levels.
      • The long-term results of the Mobi-C FDA IDE clinical trial continue to demonstrate safe and effective results.
      • Overall success rate remains higher for both one and two-level Mobi-C patients when compared to ACDF.
      • Evidence supports an advantage of Mobi-C over ACDF, especially for treating two-level disease.

"LDR is honored that Mobi-C had such a significant presence this year at the NASS annual meeting," said Christophe Lavigne, President and CEO of LDR. "We are excited to have reached this important milestone and are grateful to the IDE investigators and surgeon authors whose research and presentations on Mobi-C's five-year clinical trial data help to further inform healthcare providers from around the world."

Mobi-C IDE Study

The Mobi-C Cervical Disc, the only FDA approved disc for one and two-level use was compared to one and two-level ACDF utilizing allograft bone and anterior cervical plating with screws in an IDE trial. Results found Mobi-C to be statistically non-inferior in terms of the overall study success at 24 months of follow-up for one-level use and statistically superior in terms of the overall study success at 24 months of follow-up for two-level use.

Mobi-C Cervical Disc

Mobi-C is a cobalt chromium alloy and polyethylene mobile-bearing prosthesis specifically designed as a bone-sparing, cervical intervertebral disc replacement for both one and two-level indications. All other cervical disc prostheses are FDA approved for one-level use only. In addition to the unique mobile-bearing feature, Mobi-C offers a simplified surgical technique.

About LDR Holding

LDR Holding Corporation is a global medical device company focused on designing and commercializing novel and proprietary surgical technologies for the treatment of patients suffering from spine disorders. LDR's primary products are based on its exclusive Mobi ® non-fusion and VerteBRIDGE ® fusion technology platforms and are designed for applications in the cervical and lumbar spine. These technologies are designed to enable products that are less invasive, provide greater intra-operative flexibility, offer simplified surgical techniques and promote improved clinical outcomes for patients as compared to existing alternatives. In August 2013, LDR received approval from the U.S. Food and Drug Administration (FDA) for the Mobi-C cervical disc replacement device, the first and only cervical disc replacement device to receive FDA approval to treat both one-level and two-level cervical disc disease. For more information regarding LDR Holding and the Mobi-C Cervical Disc, visit www.ldr.com or www.cervicaldisc.com .

LDR Forward-Looking Statements

This press release contains statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief or current expectations of LDR and members of its management team with respect to LDR's future business operations as well as the assumptions upon which such statements are based, including the importance of the data regarding Mobi-C's five-year results as compared to ACDF, and the potential impact on Mobi-C sales. Factors that could cause actual results to differ materially from those contemplated within this press release can also be found in LDR's Risk Factors disclosure in its Annual Report on Form 10-K, filed on March 4, 2014, and in LDR's other filings with the SEC. LDR disclaims any responsibility to update any forward-looking statements.

©2014 LDR Holding Corporation, All Rights Reserved

Media Contact: Jon Stone (646) 747-7161

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Yoodli's No. 9 Ranking Signals Enterprise AI Traction

Updated Category News Views 58

Ninth place can be easy to dismiss until you notice the company is sitting near the top of a 500-name growth list. Yoodli's No. 9 position on Deloitte's 2026 Technology Fast 500 is a meaningful signal that its AI-based coaching and workforce-skills pitch is getting traction inside large organizations. It is not a revenue disclosure, it is not a valuation marker, and...

Continue Reading
RayNeo's Black Friday Push Tests Smart Glasses Demand

Updated Category News Views 85

A million shipped pairs is a real milestone, but holiday markdowns are where the rubber meets the road for RayNeo. The company is taking its XR gaming glasses and iO AI smart glasses into Europe’s Black Friday scrum with discounts running through late November, betting that portability, giant virtual screens and a little AI convenience can pry open consumers’ wallets....

Continue Reading
Vuzix Bets on Lightweight Color Glasses for OEM Partners

Updated Category News Views 152

Forty grams is where this story gets interesting, because faces are ruthless product testers. People will tolerate plenty of clever technology right up until it pinches, looks goofy, leaks light, or makes them feel like they are wearing a science project. Vuzix is trying to clear that hurdle with Ultralite Color, a full-color AI eyewear reference platform built for OEM...

Continue Reading
Elijah Craig Uses AI Toasts to Sell a Warmer Pour

Updated Category News Views 38

A Speech Prompt With a Bourbon Label Few things expose holiday nerves faster than a raised glass and a room waiting for somebody to say something memorable. Elijah Craig has decided that awkward little moment is marketing territory, rolling out its Digital Perfect Pour, Perfect Toast Generator for mobile and desktop users ahead of the holiday season. The tool asks for a...

Continue Reading
Halff Elevates People and Delivery Leadership Team

Updated Category News Views 103

Infrastructure outfits rarely make much noise when they reshuffle leadership, but Halff’s Nov. 18 announcement deserves a closer look than the usual executive-title confetti. The employee-owned consulting firm has put Greg Carpenter in the chief people officer seat and named Leigh Hollis chief delivery officer. One role is aimed squarely at the human machinery; the...

Continue Reading
Peptide Labels Cannot Substitute for Clinical Care

Updated Category News Views 70

A Label Is Not a Care Plan Those three little words, research use only, carry far more weight than a flashy product page would have people believe. The HelloNation article featuring wellness expert Andres Giraldo makes a plain but necessary distinction: a research-use-only, or RUO, label does not turn a peptide into prescribed treatment, and it sure does not establish...

Continue Reading
Century Complete Tests Conway Demand Near Myrtle Beach

Updated Category News Views 30

Ninety-four lots in Conway may not move Wall Street by themselves, but they can say plenty about the kind of buyer Century Communities is chasing. Century Complete is opening its model at Cates Bay Crossing on Nov. 21, 2026, with single-family homes starting in the $260s. In a housing market where affordability gets talked to death and rarely delivered cleanly, that...

Continue Reading
Vector Adds Mesa Division 10 Veteran for Arizona Growth

Updated Category News Views 85

A toilet-partition deal rarely raises eyebrows, but this one has the sturdy logic investors ought to notice. Vector Building Products has acquired Mesa-based Partitions & Accessories Co., a Division 10 specialist that has served Arizona contractors since 1978. It is not glamorous work. It is, however, the sort of necessary, specification-driven business that gets embedded...

Continue Reading
Early Dog Guarding Signs Matter Before a Sudden Growl

Updated Category News Views 92

A bowl, a chewed-up toy, or a patch of couch can turn tense in a heartbeat. That is why the useful part of Brian Manning's guidance is not some fantasy of making every dog endlessly tolerant; it is learning to notice discomfort while there is still room to back off safely. For anybody watching the pet-care and behavior-training field, this is the kind of plainspoken...

Continue Reading
Pressure Injury Care Needs More Than Awareness Alone

Updated Category News Views 52

Wet skin does not care how polished the awareness campaign looks. That is the uncomfortable truth sitting underneath Worldwide Pressure Injury Prevention Day, the annual observance held on the third Thursday of November. Pressure injuries remain a stubborn problem across healthcare facilities and home care settings because prevention is not one tidy action; it is a chain...

Continue Reading

Top 5 Most Recently Viewed Articles

Penske's Q3 2026: Revenue Up, Private Deal Awaits

Updated Category News Views 189

Jumping straight into it, Penske Automotive Group (NYSE: PAG) just rolled out their quarterly numbers. The highlights? A 5% revenue bump, landing at $8.4 billion. That's nice, sure, but let's not get too cozy, there's a bigger elephant in this garage—it's the bold move to take the company private! Our old friend volatility still sends shivers down the spine of long-time...

Continue Reading
Shanghai Hosts 20th Global Entrepreneurship Week

Updated Category News Views 226

Shanghai: A Hacker's Paradise of Innovation? The heart of financial ambition beats loud and clear in Shanghai this time of year. November 10 to 14, 2026, promises to be a spectacle of entrepreneurial valor as the city hosts the 20th Global Entrepreneurship Week China. This isn't just some run-of-the-mill networking shindig; we're talking about over 50 dazzling events,...

Continue Reading
Strategic Merger of BerGenBio and Oncoinvent Bolsters Growth

Updated Category News Views 247

BerGenBio and Oncoinvent Proposed Merger Overview In a significant development within the biotechnology sector, BerGenBio ASA and Oncoinvent ASA have announced their plans for a merger. The merger aims to combine both companies into a single entity with BerGenBio as the acquiring company, fostering a collaborative approach to advancing innovative cancer therapies. Details...

Continue Reading
Cloud-Native Application Protection Platform Market Sees Surge

Updated Category News Views 89

Cloud-Native Application Protection Platform Market Surge The Cloud-Native Application Protection Platform (CNAPP) market is witnessing remarkable growth, recently reported to be nearly $700 million in the second quarter of 2024. This represents a staggering 42 percent increase year-over-year. The recent findings emphasize how companies are prioritizing cloud security as...

Continue Reading
Arkay Zero Proof's Bold Move with $6 Million Times Square Launch

Updated Category News Views 319

Arkay Zero Proof Takes Times Square by Storm with Major Campaign Arkay Zero Proof, known for its innovative non-alcoholic spirits, is making headlines with a bold advertising initiative in the bustling Times Square. With a remarkable investment of $6 million, this campaign aims to enhance Arkay's brand visibility while reinforcing its position in the thriving market of...

Continue Reading